French device company Biocorp announced that it has signed an agreement with Lindal Group subsidiary VARI under which VARI will incorporate Biocorp’s Inspair inhaler sensor into its devices in a deal that includes exclusivity for countries in South America, Southeast Asia, Eastern Europe, and the Middle East.
Biocorp announced the launch of the Inspair sensor in October 2016. The sensor, which can be fitted on to most MDI actuators, records actuation data and transmits the data via Bluetooth in real time. The device also provides feedback to the patient designed to improve coordination of actuation and inhalation.
Biocorp Chief Operating Officer Eric Dessertenne commented, “Chronic lung diseases affect an increasing number of people who need solutions to improve compliance. Signing this contract is a step forward in the field of connected health. Lindal is a major player in the market and this partnership is a significative opportunity for providing connectivity features to the end patient and help him to better manage his treatment.“
VARI Sales Director Sergio Monti said, “This partnership with Biocorp will enhance Lindal product portfolio with a highly innovative offering in a context where connected health is getting more and more popular. Patients are very keen on collecting their health data to actively manage their therapy by sharing it with their doctor. This technology is particularly interesting for people with chronic diseases, like asthma or COPD, helping them to easily and accurately adjust their treatment.“
Read the Biocorp press release.
